Why Catalyst Pharmaceuticals (CPRX) Is On Investors’ Radar

Catalyst Pharmaceuticals (CPRX) has attracted attention after recent share moves, with the stock last closing at $24.98 and showing positive total returns over the past year and past 3 months.

Investors are also weighing the company’s value score of 6 and its US$3b market cap, as well as its focus on commercial treatments for rare diseases through products such as Firdapse, Fycompa, and AGAMREE.

The recent 5.05% 7 day share price return and 10.63% 90 day share price return suggest momentum has been building, while the 14.53% 1 year total shareholder return and very large 5 year total shareholder return point to a strong longer term record.

If you are looking beyond rare disease plays, this could be a good moment to widen your search with 37 healthcare AI stocks

With Catalyst trading at $24.98 alongside a value score of 6 and an estimated intrinsic discount of about 61%, the key question is whether the stock is genuinely undervalued or whether the market is already pricing in future growth.

Price-to-Earnings of 14.2x: Is it justified?

On a P/E of 14.2x, Catalyst Pharmaceuticals looks inexpensive relative to both the wider US biotechs industry on 16.2x and a peer group average of 30.4x. This points to the market assigning a lower earnings multiple despite the company trading at $24.98.

The P/E ratio compares the current share price to earnings per share, so it essentially shows how much investors are willing to pay for each dollar of current earnings. For a profitable commercial stage rare disease business, this is a useful yardstick because earnings are already flowing through the income statement rather than sitting purely in the research pipeline.

Here, the current P/E of 14.2x sits under both the industry average of 16.2x and an estimated fair P/E of 14.8x. These levels suggest the market is not assigning a premium despite high quality earnings, a 22.5% return on equity and net profit margins of 36.4%. If sentiment were to shift closer to the peer average multiple near 30.4x, or even toward the fair ratio of 14.8x, that would imply room for the valuation multiple to move up from where it is today.

Result: Price-to-Earnings of 14.2x (UNDERVALUED)

However, the story can change quickly if key rare disease products face competitive pressure, or if US$588.989m in US based revenue becomes harder to sustain.

Another View: Cash Flows Point To Deeper Value

While the 14.2x P/E implies Catalyst is only modestly cheap, the SWS DCF model tells a different story. With the share price at $24.98 and a DCF value of $63.36, the stock screens as heavily undervalued and raises the question of whether earnings or cash flows are giving the clearer signal.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Catalyst Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of low multiples and strong profitability has caught your eye, take a closer look at the numbers yourself and decide quickly how you feel about the opportunity. To see what is currently exciting more optimistic investors, check out the 5 key rewards

Looking for more investment ideas?

If Catalyst has sharpened your focus, do not stop here. Broaden your watchlist now or risk missing other stocks that could fit your goals.

• Spot potential value standouts early by scanning screener containing 25 high quality undiscovered gems before they attract wider attention.
• Strengthen your portfolio’s foundation with companies screened through the solid balance sheet and fundamentals stocks screener (40 results) that prioritise financial resilience.
• Target dependable cash returns by reviewing the 13 dividend fortresses and zeroing in on higher yielding income ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.